%0 Journal Article
%T The impact of COVID-19 on clinical course and treatment among patients with juvenile systemic sclerosis.
%A Adrovic A
%A Yıldız M
%A Haşlak F
%A Şahin S
%A Köker O
%A Günalp A
%A Barut K
%A Kasapçopur Ö
%J Arch Rheumatol
%V 38
%N 2
%D 2023 Jun
%M 37680509
暂无%R 10.46497/ArchRheumatol.2023.9636
%X <B>UNASSIGNED: </B>This study aimed to explore the influence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic among patients with juvenile systemic sclerosis (JSS).<BR><B>UNASSIGNED: </B>Twenty-seven patients (22 females, 5 males; mean age: 20 years; range, 17 to 22 years) diagnosed with JSS and followed up at the department of pediatric rheumatology were included in the cross-sectional study. A web-based survey was performed by focusing on patients' complaints, accessibility to health care, and compliance with routine treatment from January 1, 2021, to January 10, 2021.<BR><B>UNASSIGNED: </B>Five (18.5%) patients had deterioration of the disease, while six (22.2%) patients reported irregular usage of their routine scleroderma treatment during the last six months. Nine (33.3%) patients had missed their routine clinic control since the proclamation of the SARS-CoV-2 pandemic. Seven (25.9%) patients had household contact with coronavirus disease 2019 (COVID-19). Four (14.8%) patients were diagnosed with COVID-19, and only one (3.7%) was hospitalized. Nine patients were under biological treatment (tocilizumab); however, only one of them was diagnosed with COVID-19.<BR><B>UNASSIGNED: </B>The COVID-19 pandemic has not significantly disrupted the medical care of JSS patients. Telemedicine could be an acceptable option for JSS patients disenabled to come to the hospital.